stockrowEstablishment Labs Holdings Inc.
ESTA Healthcare Medical Devices
Establishment Labs Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $211.1 million, up 27.1% from fiscal 2024.
- Revenue
- +31.7%
- EPS
- +31.6%
- Free cash flow
- +2.75%
- Total debt
- +18.3%
Quarter to June 2026, against a year earlier
Follow ESTA
Alert me
Establishment Labs Holdings Inc. (ESTA) EV/Sales
As of 5 November 2026, Establishment Labs Holdings Inc. (ESTA) trades at a EV/Sales of 8.7×. Over the past ten years it has ranged from 2.1× (March 2020) to 22.7× (June 2021); the current reading is higher than 46% of that period. That is above the Medical Devices industry median of 2.7× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 11.1× | 27.76% |
| FY2024 | 8.7× | 69.31% |
| FY2023 | 5.2× | (49.96%) |
| FY2022 | 10.3× | (20.50%) |
| FY2021 | 12.9× | 26.85% |
| FY2020 | 10.2× | 52.36% |
| FY2019 | 6.7× | (12.15%) |
| FY2018 | 7.6× | (11.42%) |
| FY2017 | 8.6× | 0.00% |
| FY2016 | 8.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 11.4× | 37.31% |
| Mar 2026 | 8.3× | (25.64%) |
| Dec 2025 | 11.1× | 50.77% |
| Sep 2025 | 7.4× | (7.84%) |
| 34 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CNMD CONMED Corporation compare | 1.7× |
| NVCR NovoCure Limited compare | 1.8× |
| INSP Inspire Medical Systems, Inc. compare | 1.8× |
| NEOG Neogen Corporation compare | 3.6× |
| UFPT UFP Technologies, Inc. compare | 3.7× |
| TMDX TransMedics Group, Inc. compare | 3.8× |
| ESTA Establishment Labs Holdings Inc. | 8.7× |
| BFLY Butterfly Network, Inc. compare | 12.5× |
| ALMR Alamar Biosciences, Inc. compare | 15.6× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)